

DRIVE RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE

February 2016

Remember: Clicking the [coloured links](#) will take you to more information!



Don't forget: DRIVE-AB is on [Twitter](#)! Don't miss out - follow us at [@DRIVE_AB](#).

Interested in getting involved? Just go to our website and click "[Stakeholder Engagement](#)" to find out all you need to know about getting involved with the project!

SAVE THE DATE! DRIVE-AB Final Conference



The [DRIVE-AB Final Conference](#) will be held on the **5th to 6th of September 2017** in **Brussels, Belgium** at the **Crowne Plaza**. The conference will bring together high-level policy makers, regulatory and public health experts, economists and representatives of pharmaceutical companies, the medical community and civil society to discuss DRIVE-AB results and recommendations and suggest solutions for their implementation around the globe. If you wish to attend, please register your interest with Victoria Wells (VWells@BSAC.org.uk).

DRIVE-AB Recommended Reward Models to be Released in June

DRIVE-AB work packages have been working hard to finalize their research results, and that hard work is about to pay off! DRIVE-AB's recommended models to incentivise antibiotic discovery and development will be released in a **policy brief ahead of the G20 meeting** on 7-8 July 2017. This

will be followed in September by a report on possible solutions for reward model implementation worldwide.



DRIVE-AB will be well represented at this year's **European Congress on Clinical Microbiology and Infectious Diseases (ECCMID)**, which will be held from **22 - 25 April 2017** in Vienna, Austria. The consortium has submitted a total of six abstracts covering topics ranging from barriers and facilitators of responsible antibiotic use to the modelling the global spread of antibiotic-resistant bacteria and will have a presence at the European Networking Corner. [Click here to read more.](#)



DRIVE-AB is co-hosting a **workshop: Sustainable use policies within a new multi-sectoral framework for antibiotics**. Held in collaboration with **CARB-X** and the **Brocher Foundation**, this small, invitation-only workshop will bring together some of our key stakeholders to focus on sustainable use policies within a new multi-sectoral framework for antibiotics. The workshop will take place on **18-19 May 2017 in Geneva, Switzerland**. [Click here to read more.](#)



The **International Conference on Prevention and Infection Control (ICPIC)** will be held in Geneva, Switzerland on **20 - 23 June 2017** and will feature a DRIVE-AB symposium. The symposium, "Responsible antibiotic use and new developments", will be held on **Friday 23 June** from 09:00 - 10:30. [Click here to see the conference website for more details.](#)

Additional Recent DRIVE-AB Outputs

- **Publication: "An antibiotic's journey from marketing authorization to use Norway"**
Bulletin of the World Health Organization article (Online First publication) written by WP2 partners. 19 January 2017.
- **Abstracts submitted to the European Congress on Clinical Microbiology and Infectious Diseases (ECCMID)** - abstracts available April 2017
 1. "Views and experiences of currently or recently hospitalized patients in four European countries with regard to barriers and facilitators to responsible antibiotic use: a qualitative descriptive study"
 2. "Barriers and facilitators of responsible systemic antibiotic use from the patient's perspective: a systematic review"
 3. "Towards a global definition of responsible antibiotic use. Results of the DRIVE-AB project"
 4. "The Impact of Antibiotic Use on Transmission Dynamics of Antibiotic-Resistant Bacteria in the Hospital Setting"
 5. "Identification and modeling of antibiotic-resistant bacteria worldwide"
 6. "Estimating the current number of Third-Generation Cephalosporin-resistant E. coli and K. pneumoniae infections worldwide"

To view all DRIVE-AB outputs to date, please see our website.

What Have We Been Up To?

DRIVE-AB Partners Interviewed for Boston Consulting Group Report

DRIVE-AB partners were interviewed to provide input for the Boston Consulting Group follow-up report for the German Global Union for Antibiotics Research and Development (GUARD) Initiative, **“Breaking through the wall: A call for concerted action on antibiotics research and development”**. The consortium is referenced in the report as a driver of funding and coordination for research and development of antibiotics. [Click here to read the full report.](#)

DRIVE-AB SME Stakeholder Meeting

A **one-day workshop** was held on **16 January 2017** at Chatham House in London, UK. 11 European SMEs (all members of BEAM) and the UK Antimicrobial Resistance Centre were represented to discuss and to express their views on DRIVE-AB’s research on models/incentives, both in regards to overall structure and combination across the antibiotic R&D pipeline as well as the details of single incentives. In general, SMEs would benefit from risk-sharing tools and improved funding for early phases of development. Exit options and milestone payments are important for SMEs as many of them don’t see their role to advance a new drug to the market. [Click here to read more.](#)

DRIVE-AB Work Referenced Throughout Duke Margolis Report

The Duke Margolis Center for Health Policy released a report in November 2016 titled, **“Tracking the progress of economic incentives for antimicrobial drug development in the U.S. and across the globe”**. DRIVE-AB and its short-list of economic models, which were presented at the mid-term conference last year, are referenced throughout the document. [Click here to read the full report.](#)

Project updates by work package

Responsible use of antibiotics, new and old

In addition to submitting three abstracts to the 2017 European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), the team is preparing a series of articles to be published in the *Journal of Antimicrobial Chemotherapy* in individual issues throughout 2017. The definition of “responsible use” has engaged with stakeholders from a variety of backgrounds to help the group to evaluate the feasibility of their agreed metrics and indicators in different settings, identify how they can be applied in clinical settings, facilitate the implementation of antimicrobial stewardship policies and create educational materials. [To read a summary of their most recent stakeholder meeting on 28 September 2016, please click here.](#) For more detailed information on the group’s progress please see their [stakeholder engagement page](#).

Setting, communicating and revising public health priorities

In addition to having three abstracts accepted for ECCMID 2017, the group continues to work on the development of simulation models to predict transmission and spread of antibiotic-resistant bacteria. The team has been generating incidence data for key pathogens and has data-mined large multi-drug resistant organisms (MDRO) surveillance systems to model patterns of spread; to disseminate results, the group is creating a website featuring maps that display the estimated current and future number of MDRO infections by country. The team is also working on a systematic review exploring the impact of tourism, medical tourism, and immigration on MDR spread. Epidemiological data that the team has generated have been used as basis for evidence-based criteria for the World Health Organization Priority Pathogen List, which will be published soon. For more detailed information on the group’s progress please see their [stakeholder engagement page](#).

[Antibiotic Evaluation](#)

The team is finalizing manuscripts on a framework for valuing antibiotics as well as lessons learned from the pre-antibiotic era and has completed stakeholder interviews and expert elicitation to estimate the burden of antimicrobial resistance. For more detailed information on the group's progress or to register your interest in attending the stakeholder meeting please see their [stakeholder engagement page](#).

[Creation and testing of new economic models](#)

In addition to publishing their article in the Bulletin of the World Health Organization, "[An antibiotic's journey from marketing authorization to use Norway](#)", the team is working to finalise their shortlist of incentives and reward models to stimulate investment in antibiotic R&D. This includes an operational assessment of a delinked incentive. They are also designing sustainable use and equitable availability policies. The team will begin writing their final report and the recommendations for implementation in the spring of 2017 along with two policy briefs which will be directed at the World Health Assembly and the G20 Presidency. For more detailed information on the group's progress please see their [stakeholder engagement page](#).

[Project management and governance](#)

Along with ongoing project monitoring and management activities, the team has appointed a conference organizing committee to assist WP3A and WP3B in the organization of the final **DRIVE-AB Conference**, which will be held on **5-6 September 2017** at the **Crowne Plaza** in **Brussels, Belgium**. For more detailed information on the group's progress please see their [webpage](#).

[Stakeholder platform and external communication](#)

In addition to managing internal and external communications through oversight of the DRIVE-AB communications strategy, website and social media, the team continues to coordinate the engagement of existing and novel stakeholders. They are also busy working with WP3A to organize the final DRIVE-AB Conference. For more detailed information on the group's progress please see their [webpage](#).

[Edit your subscription](#) | [Unsubscribe](#)